KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Liabilities (2016 - 2025)

Astrazeneca has reported Total Liabilities over the past 11 years, most recently at $65.4 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $65.4 billion for Q4 2025, up 3.47% from a year ago — trailing twelve months through Dec 2025 was $65.4 billion (up 3.47% YoY), and the annual figure for FY2025 was $65.4 billion, up 3.47%.
  • Total Liabilities for Q4 2025 was $65.4 billion at Astrazeneca, up from $63.2 billion in the prior quarter.
  • Over the last five years, Total Liabilities for AZN hit a ceiling of $66.1 billion in Q4 2021 and a floor of $59.4 billion in Q4 2022.
  • Median Total Liabilities over the past 5 years was $63.2 billion (2024), compared with a mean of $63.2 billion.
  • Biggest five-year swings in Total Liabilities: grew 29.33% in 2021 and later decreased 10.07% in 2022.
  • Astrazeneca's Total Liabilities stood at $66.1 billion in 2021, then decreased by 10.07% to $59.4 billion in 2022, then increased by 4.25% to $62.0 billion in 2023, then grew by 1.95% to $63.2 billion in 2024, then rose by 3.47% to $65.4 billion in 2025.
  • The last three reported values for Total Liabilities were $65.4 billion (Q4 2025), $63.2 billion (Q4 2024), and $62.0 billion (Q4 2023) per Business Quant data.